<DOC>
	<DOCNO>NCT01408394</DOCNO>
	<brief_summary>Ecopipam hydrochloride ( HCl ) investigational drug study several possible disease . To date , clinical study do use ecopipam immediate release ( IR ) tablet . However , control release ( CR ) capsule formulation ecopipam produce may able improve effectiveness reduce side effect . The main purpose study evaluate safety tolerability ecopipam CR capsule give single oral dose healthy volunteer .</brief_summary>
	<brief_title>Safety Tolerability Comparison Immediate Controlled Release Formulations Ecopipam</brief_title>
	<detailed_description>Ecopipam hydrochloride ( HCl ) investigational drug study several possible disease . To date , clinical study do use ecopipam immediate release ( IR ) tablet . However , control release ( CR ) capsule formulation ecopipam produce may able improve effectiveness reduce side effect . The main purpose study evaluate safety tolerability ecopipam CR capsule give single oral dose healthy volunteer . Another purpose study measure much CR IR ecopipam get blood stream , long body take get rid . Information side effect may occur collect .</detailed_description>
	<mesh_term>Ecopipam</mesh_term>
	<criteria>1 . Signed date , IRBapproved inform consent form protocolspecific screening procedure 2 . Nonsmoking male subject age 18 45 year ( inclusive ) 3 . In good general health determine thorough medical history physical examination , ECG , vital sign , clinical laboratory evaluation 4 . Willing able complete study assessment procedures 5 . Body mass index ( BMI ) 18 30 kg/m2 ( inclusive ) weight 65 100 kg ( inclusive ) 6 . QTcB interval ( Bazett 's correction factor ) baseline ECG must ≤ 450 m screen 1 . Subjects history suicide attempt past current active suicidal ideation 2 . Subjects history seizure head trauma leading loss consciousness 3 . Subjects clinically significant neurologic , cardiovascular , hepatic , renal , endocrinologic , pulmonary , hematological , psychiatric , medical illness would interfere participation study 4 . History primary malignancy , exception basal cell squamous cell carcinoma skin cervical carcinoma situ malignancy curatively treat evidence disease least 5 year 5 . Supine blood pressure &gt; 140/90 mm/Hg rest heart rate ≥100 bpm screen visit 6 . History substancerelated disorder ( exception caffeinerelated nicotinerelated disorder ) eat disorder define Diagnostic Statistical Manual Mental Disorders ( DSMIVTR ) within 1 year screen 7 . History smoking use nicotine containing product within 3 month screen self report 8 . A positive alcohol Breathalyzer urine drug screen drug abuse screen visit begin inpatient period 9 . Treatment investigational drug within 30 day 5 halflives ( whichever longer ) prior begin screen period 10 . Treatment prescription nonprescription drug ( include vitamin , herbal , dietary supplement ) within 7 day 5 halflives screen visit , whichever longer . Acetaminophen permit intermittent treatment dose less 2 grams/day 11 . Subjects history previous administration ecopipam allergic reaction hypersensitivity drug component CR formulation 12 . Blood collection blood loss great 500 mL within 56 day prior screen 13 . Positive human immunodeficiency virus ( HIV ) screen 14 . Positive Hepatitis B surface antigen ( HbsAg ) positive Hepatitis C virus ( HCV ) antibody screen 15 . Any condition and/or situation cause investigator deem subject unsuitable study ( e.g. , due expect study medication noncompliance , inability medically tolerate study procedure , subject 's unwillingness comply studyrelated procedure )</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>May 2013</verification_date>
	<keyword>safety</keyword>
	<keyword>pharmacokinetics</keyword>
	<keyword>control release</keyword>
	<keyword>formulation</keyword>
</DOC>